Could a chemo combo save lungs in scleroderma patients?
NCT ID NCT01570764
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether a combination of the chemotherapy drug cyclophosphamide and the steroid prednisone could help people with scleroderma-related lung disease. Forty adults whose lung function had worsened in the past year received either the drug combo or a placebo plus prednisone for 12 months. The goal was to see if the treatment could stabilize or improve lung volume and gas exchange.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cyclophosphamide (chemotherapy drug) plus prednisone (steroid)
What this could lead to
If it works, this could offer a way to slow or stop lung decline in people with scleroderma-related lung disease.
What could go wrong
This is a small, completed phase 3 trial with only 40 participants. Cyclophosphamide can have serious side effects, and the benefit may not be large or lasting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cochin Hospital
Paris, 75014, France